Role of MicroRNAs in Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Parkinson’s disease (PD) is a disabling neurodegenerative disease that manifests with resting tremor, bradykinesia, rigidity and postural instability. Since the discovery of microRNAs (miRNAs) in 1993, miRNAs have been shown to be important biological molecules involved in diverse processes to maintain normal cellular functions. Over the past decade, many studies have reported dysregulation of miRNA expressions in PD. Here, we identified 15 miRNAs from 34 reported screening studies that demonstrated dysregulation in the brain and/or neuronal models, cerebrospinal fluid (CSF) and blood. Specific miRNAs-of-interest that have been implicated in PD pathogenesis include miR-30, miR-29, let-7, miR-485 and miR-26. However, there are several challenges and limitations in drawing definitive conclusions due to the small sample size in clinical studies, varied laboratory techniques and methodologies and their incomplete penetrance of the blood–brain barrier. Developing an optimal delivery system and unravelling druggable targets of miRNAs in both experimental and human models and clinical validation of the results may pave way for novel therapeutics in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Prediction of Mammalian MicroRNA Targets
Lewis, B. P., Shih, I.-H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003) · Cell · doi:10.1016/s0092-8674(03)01018-3 · Cited by 5,199 · cited 1×
“The specificity of the targeting is especially dependent on the seed sequence of the miRNA found at the 5′-end (bases 2–8) of the miRNA [16,17].”
BackgroundEpidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110 · cited 1×
“An estimated prevalence of 1% of people above 60 years old suffer from PD [1].”
BackgroundThe Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease
Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310
St-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233 · cited 2×
“Moreover, PGC-1α knockout mice displayed an increased vulnerability to MPTP-induced degeneration of nigral DA neurons [104].”
BackgroundBrochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172 · cited 1×
“Blood-brain barrier (BBB) compromise and peripheral immune components infiltration have also been reported in PD patients [12,13].”
BackgroundMicroRNA functions in stress responses
Leung, A. K. L., & Sharp, P. A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.027 · Cited by 865
Parkinson's Disease and Parkinsonism
Hayes, M. T. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.03.001 · Cited by 823
Blood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
Gui, Y., Liu, H., Zhang, L., Lv, W., & Hu, X. (2015) · Oncotarget · doi:10.18632/oncotarget.6158 · Cited by 552 · cited 25×
“…and Roy, 2017 [27] miR-543 3 Tatura et al., 2016 [27]; Nelson et al., 2018 [46]; Mo et al., 2017 [49] - - miR-136 3 Chatterjee and Roy, 2017 [27] Gui et al., 2015 [30]; Burgos et al., 2014 [35] Chatterjee and Roy, 2017 [27] miR-1 3 Asikainen et al., 2010 [40] Gui et al., 2015 [30] Margis et…”
BackgroundInfluential
Cited by
Bai, X., & Bian, Z. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.842288 · Cited by 66
MiRNA: Involvement of the MAPK Pathway in Ischemic Stroke. A Promising Therapeutic Target
Gugliandolo, A., Silvestro, S., Sindona, C., Bramanti, P., & Mazzon, E. (2021) · Medicina · doi:10.3390/medicina57101053 · Cited by 49
Li, X., Zhao, J., Li, Z., Zhang, L., & Huo, Z. (2020) · Neural Plasticity · doi:10.1155/2020/8850653 · Cited by 35
“Specific miRNAs of interest that have been implicated in PD pathogenesis include miR-29, miR-26, miR-485, miR-30, and let-7 [53].”
BackgroundThe role of microRNA-485 in neurodegenerative diseases
Ryu, I. S., Kim, D. H., Cho, H.-J., & Ryu, J.-H. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0039 · Cited by 25
Pereira, C. P. M., Francis-Oliveira, J., Singulani, M. P., Ferreira, A. F. F., & Britto, L. R. G. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578019 · Cited by 22
MiRNA-1976 Regulates the Apoptosis of Dopaminergic Neurons by Targeting the PINK1 Gene
Qiu, F., Wu, Y., Xie, G., Cao, H., Du, M., & Jiang, H. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2202045 · Cited by 11
miRNA family miR-29 inhibits PINK1-PRKN signaling via ATG9A
Markham, B. N., Ramnarine, C., Kim, S., Grever, W. E., Soto-Beasley, A. I., Heckman, M. G., Ren, Y., Osborne, A. C., Kehili, M., Bhagwate, A. V., et al. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00029-w · Cited by 7
Metadata
- Authors
- Goh, S. Y., Chao, Y. X., Dheen, S. T., Tan, E.-K., & Tay, S. S.-W.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-11-12
- Volume
- 20
- Issue
- 22
- Pages
- 5649
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2988080152
- Cited by
- 179
- References
- 28
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.